Related Experiment Video
Updated: Feb 3, 2026

Studying Wnt Signaling During Patterning of Conducting Airways
Published on: October 16, 2016
Liver X receptor activation reduces gastric cancer cell proliferation by suppressing Wnt signalling via LXRβ
Qiang Wang1, Fan Feng2, Jiayou Wang1
1Institute of Life Sciences, Jiangsu University, Zhenjiang, China.
Abstract:
Liver X receptors (LXRs) are involved in various diseases associated with lipid disorders, and in regulating cancer cell proliferation. However, the underlying molecular mechanisms, especially those in gastric cancer (GC) remain to be clarified. In this study, immunohistochemistry analysis revealed that LXRβ was mainly expressed in GC tissue, with less expression in adjacent normal tissues. The LXRβ agonist T0901317 efficiently suppressed the proliferation and colony formation of various GC cell lines. We further showed that LXRβ translocated from the cytoplasm to the nucleus when activated by T0901317. LXRβ nuclear localization suppressed the activation of Wnt signalling and decreased the expression of target genes such as MYC, BMP4, and MMP7 through binding to their promoters. Moreover, we demonstrated that the LXR agonist efficiently suppressed GC tumour growth in a nude mouse xenograft model. Taken together, these results revealed that LXRβ agonist inhibited GC cells proliferation by suppressing Wnt signalling via LXRβ relocalization. The results strongly suggest that LXRβ could be a promising target in GC therapy.
Insights
Liver X receptor beta (LXRβ) activation suppresses gastric cancer (GC) cell growth by inhibiting Wnt signaling. This research highlights LXRβ as a potential therapeutic target for GC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Liver X receptors (LXRs) are implicated in lipid disorders and cancer cell proliferation.
- Molecular mechanisms of LXR action in gastric cancer (GC) require further elucidation.
Purpose of the Study:
- To investigate the role and therapeutic potential of LXRβ in gastric cancer.
- To elucidate the molecular pathways targeted by LXRβ activation in GC.
Main Methods:
- Immunohistochemistry to assess LXRβ expression in GC tissues.
- In vitro studies using GC cell lines treated with an LXRβ agonist (T0901317).
- In vivo studies using a nude mouse xenograft model of GC.
Main Results:
- LXRβ was predominantly expressed in GC tissues compared to normal adjacent tissues.
- LXRβ agonist T0901317 inhibited GC cell proliferation and colony formation.
- T0901317 induced LXRβ nuclear translocation, suppressing Wnt signaling and decreasing expression of target genes (MYC, BMP4, MMP7).
- LXRβ agonist treatment suppressed GC tumor growth in vivo.
Conclusions:
- LXRβ activation inhibits gastric cancer cell proliferation by suppressing Wnt signaling through LXRβ nuclear relocalization.
- LXRβ represents a promising therapeutic target for gastric cancer treatment.
Related Concept Videos
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
What is Cell Signaling?
Cell-surface Signaling
Signal Sequences and Sorting Receptors
Insulin: The Receptor and Signaling Pathways

